For the estimated 5 million people in the United States with AF, several treatment approaches are used, each with a wide range of pharmacological options. The established guidelines recommend the use of rate control and rhythm control strategies to establish a normal sinus rhythm, accompanied by use of antithrombotic therapy for stroke risk reduction. This report provides a quantitative analysis of treatment patterns and patient share by line of therapy as well as progression between lines, duration of treatment, and use of concomitant treatment for newly diagnosed AF patients. It also quantifies a drug’s source of business and details which drugs precede others through an analysis of add-versus-switch patterns for recently treated patients. Additional analyses explore persistency and compliancy by brand.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed AF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AF patients?
- How have NOACs been integrated into the treatment algorithm, and what is the source of business for each?
- What proportion of AF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of AF patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with AF?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: Bayer, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Boehringer Ingelheim.
Key drugs: Xarelto, Eliquis, Savaysa, Pradaxa, warfarin, amiodarone, metoprolol.
Key analysis provided:
- Brand use across a longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
- Atrial Fibrillation - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis
Author(s): Shreya Saxena, MBA
Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group.
She obtained an M.B.A. degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.